Meta's AI glasses get FDA-cleared hearing aid software: what the clearance shows

Meta announced on 24 September 2026 that an FDA-cleared hearing aid feature, which it calls Hearing Enhancement, will be sold as a $149.99 add-on for supported AI glasses in the United States later this year. FDA records show the software, filed as "Hearing assist", was cleared on 13 July 2026 as an over-the-counter hearing aid for adults with perceived mild to moderate hearing loss. The clearance documents say a good deal more than the launch announcement did.

What happened

Meta described the feature in a newsroom post summarising its Connect event, published on 24 September 2026. The company calls it "FDA-cleared software that helps adults with perceived mild to moderate hearing loss hear better" and says it "can be set up at home in minutes", with "no clinic or prescription needed". It will cost $149.99, which Meta describes as HSA and FSA eligible, or come included with a Meta One subscription. Meta says it is "launching in the US later this year" and will be "available to add to supported AI Glasses". The post does not name the supported models or give a launch date.

The regulatory paperwork is public. The FDA's 510(k) database lists submission K254044, a device named "Hearing assist" from Meta Platform Technologies, received on 17 December 2025 and cleared on 13 July 2026 with a finding of "substantially equivalent". It is a Class II device under 21 CFR 874.3335, "air-conduction hearing aid software", product code SCR, reviewed by the FDA's ear, nose and throat specialists.

How the software works, according to the FDA summary

The 510(k) summary that Meta filed, and the FDA published, describes two pieces of software: an app on a compatible iOS phone and firmware that runs on the glasses. During setup the user wears the glasses while the app plays test tones through them and builds a "hearing profile" for each ear. The glasses then use their own microphones and speakers to pick up surrounding sound and play it back amplified according to that profile. Users can adjust volume, sharpness and balance, and can set the microphones to an all-around mode or a frontal "focus" mode.

The summary also lists technical figures. Hearing assist "is designed to last at least 3 hours of continuous use on fully charged Smart Glasses", with a charging case. Measured latency is 9.25 milliseconds and maximum output (OSPL90) is 108.6 dB SPL, both stated to meet the FDA's OTC hearing aid requirements. Unlike earbuds, the glasses deliver sound "without the device obstructing the ear canal".

The clinical study

The summary reports a study of 142 adults at three US sites (registered as NCT07115979). Participants had a lab session and then used the device at home and in the community for 14 days. One group fitted the device themselves; the other had it fitted by a licensed hearing care professional. On the main measure, a questionnaire called the International Outcome Inventory for Hearing Aids, the self-fit group scored 25.77 on average and the professionally fitted group 26.81, and the self-fit approach was found statistically non-inferior. On a speech-in-noise test the two groups were also comparable. Compared with no device, self-fitted users showed an average speech-in-noise benefit of 4.8 dB.

On safety, the summary reports six device-related adverse effects in five of the 142 participants: five reports of headache and one of tiredness, described as mild and transient. Two participants had serious adverse events, a fall and a cardiac event, which the summary says were unrelated to the device. These results come from the company's own submission. We did not find a peer-reviewed publication of the study.

The background

Hearing aids in the US were long sold through licensed professionals. The FDA created an over-the-counter category by a final rule published on 17 August 2022, which took effect on 17 October 2022. The FDA says OTC hearing aids are for people aged 18 and over with perceived mild to moderate hearing loss, who can buy them without a medical exam, a prescription or a fitting by an audiologist. In its economic analysis of the rule, the FDA estimated consumer benefits of between $6 million and $147 million a year.

Software-only hearing aids came next. On 12 September 2024 the FDA authorised the Hearing Aid Feature for Apple's AirPods Pro through its De Novo pathway, which is used for new types of low to moderate risk devices. That decision created the regulation and product code Meta's software now sits under, and Apple's feature (DEN230081) is the predicate device Meta compared itself against. Glasses are not new to the category either: Meta's own summary points to K243150, which openFDA lists as "Nuance Audio Hearing Aid Software" from Luxottica Group, cleared on 31 January 2025.

A 510(k) clearance is not the same as an FDA approval. It means the FDA agreed the device is substantially equivalent to one already legally on the market. The clearance also included a "Predetermined Change Control Plan", which lets Meta add an Android version of the phone app without a new submission, provided it follows the testing set out in that plan.

Why it matters

The FDA said in 2024 that more than 30 million American adults report some degree of hearing loss, and that research has linked hearing aid use to reductions in cognitive decline, depression and other problems in older adults. A feature that can be added to glasses some people already wear, with setup at home, may make a first step easier for some of them. That is a reasonable expectation, not a proven outcome: nobody has yet published data on who takes it up or how they use it.

There are trade-offs to weigh. The open-ear design is different from earbuds and traditional hearing aids that sit in the ear canal; the 510(k) summary states that bench and clinical testing found these differences raised no new safety or effectiveness questions. The rated three hours of continuous use is short of a full waking day, so how people top up the glasses during the day will matter. And the evidence so far is a single, company-sponsored study over 14 days of home use.

For the industry, the clearance shows a repeatable route: build on an earlier software-only authorisation, show that self-fitting works as well as professional fitting, and use a change control plan to extend to new phones.

What we do not know yet

• Which glasses. Meta has not said which models will support the feature.
• When. Meta says "later this year" but gives no date.
• Which phones. The FDA summary describes an iOS app at clearance, with Android planned under the change control plan. Meta has not said whether Android will be supported at launch.
• Real-world battery life. The three-hour figure is for continuous hearing assist use. How it changes with other glasses features running is not stated.
• Return terms. The FDA requires OTC hearing aid makers to disclose their return policy but does not set one. Meta's announcement did not describe a trial or return period.
• Independent evidence. No independent or peer-reviewed evaluation of the feature has been published that we could find.

What it means for you

If you are thinking about any OTC hearing aid, including this one, the FDA's consumer guidance is a sensible starting point. OTC devices are for adults with perceived mild to moderate hearing loss, the kind that shows up as trouble following conversations in noisy places or in groups, or needing the TV louder than others do.

The FDA advises seeing a doctor, preferably an ear, nose and throat specialist, before using an OTC hearing aid if you have:

• ear pain, or fluid, blood or pus coming from the ear;
• a sudden change in hearing, or hearing that is much worse in one ear;
• significant dizziness or vertigo;
• ringing in only one ear;
• difficulty hearing loud sounds such as power tools or engines.

Before buying, check the seller's return terms so you have time to adjust to amplification. If you plan to use an HSA or FSA, confirm eligibility with your plan. A hearing test with an audiologist or your clinician can tell you whether an OTC option suits your level of hearing loss. Problems with a hearing aid, such as worsening hearing or skin irritation, can be reported to the FDA through MedWatch online or by calling 1-800-FDA-1088.